Determination of burn patient outcome by large-scale quantitative discovery proteomics

Critical Care Medicine

Volumn 41, Issue 6, 2013, Pages 1421-1434

  Finnerty, Celeste C ^a,b   Jeschke, Marc G ^c   Qian, Wei Jun ^d   Kaushal, Amit ^e   Xiao, Wenzhong ^e   Liu, Tao ^d   Gritsenko, Marina A ^d   Moore, Ronald J ^d   Camp, David G ^d   Moldawer, Lyle L ^f   Elson, Constance ^g   Schoenfeld, David ^g   Gamelli, Richard ^h   Gibran, Nicole ⁱ   Klein, Matthew ⁱ   Arnoldo, Brett ^j   Remick, Daniel ^k   Smith, Richard D ^d   Davis, Ronald ^e   Tompkins, Ronald G ^g   Herndon, David N ^a   more..

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g SHRINERS HOSPITALS FOR CHILDREN   (United States)

^h LOYOLA UNIVERSITY CHICAGO   (United States)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

biomarker; burn; inflammation; liquid chromatographymass spectrometry; plasma proteins; proteomic profiling

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; APOLIPOPROTEIN D; ARGININE CARBOXYPEPTIDASE; ARYLDIALKYLPHOSPHATASE 1; BASIC PROTEIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8; COMPLEMENT COMPONENT C8; COMPLEMENT COMPONENT C9; COMPLEMENT FACTOR I; CONTACTIN 1; CYCLOPHILIN B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; INTER ALPHA TRYPSIN INHIBITOR; INTERLEUKIN 4; INTERLEUKIN 8; KERATIN TYPE II; LIPOPROTEIN A; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROGRANIN; PEPTIDYLPROLYL ISOMERASE; PLASMINOGEN; PROTHROMBIN; SCATTER FACTOR; SOMATOMEDIN BINDING PROTEIN; SPECTRIN;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; BIOLOGICAL FUNCTIONS; BODY SURFACE; BURN PATIENT; CELL DEATH; CELL MOTION; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SEQUENCING; HOSPITAL ADMISSION; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; INSULIN RESISTANCE; LARGE SCALE PRODUCTION; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SURVIVAL; TANDEM MASS SPECTROMETRY; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD PROTEINS; BURN UNITS; BURNS; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROGNOSIS; PROTEOME; PROTEOMICS;

EID: 84878530984     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31827c072e     Document Type: Article

References (27)

1. Peden M, McGee K, Sharma G. The Injury Chart Book: A Graphical Overview of the Global Burden of Injuries. Geneva, The World Health Organization, 2002
2. Herndon DN, Tompkins RG: Support of the metabolic response to burn injury. Lancet 2004; 363:1895-1902
3. Qian WJ, Jacobs JM, Liu T, et al: Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profling for clinical applications. Mol Cell Proteomics 2006; 5:1727-1744
4. Qian WJ, Liu T, Petyuk VA, et al: Large-scale multiplexed quantitative discovery proteomics enabled by the use of an (18)O-labeled " universal" reference sample. J Proteome Res 2009; 8:290-299
5. Silver GM, Klein MB, Herndon DN, et al: Standard operating procedures for the clinical management of patients enrolled in a prospective study of Infammation and the Host Response to Thermal Injury. J Burn Care Res 2007; 28:222-230
6. Calvano SE, Xiao W, Richards DR, et al: A network-based analysis of systemic infammation in humans. Nature 2005; 437:1032-1037
7. Finnerty CC, Jeschke MG, Herndon DN, et al: Temporal cytokine pro-fles in severely burned patients: A comparison of adults and children. Mol Med 2008; 14:553-560
8. Liu T, Qian WJ, Mottaz HM, et al: Evaluation of multiprotein immuno-affnity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics 2006; 5:2167-2174
9. Liu T, Qian WJ, Strittmatter E F, et al: High-throughput comparative proteome analysis using a quantitative cysteinyl-peptide enrichment technology. Anal Chem 2004; 76:5345-5353
10. Qian WJ, Monroe ME, Liu T, et al: Quantitative proteome analysis of human plasma following in vivo lipopolysaccharide administration using 16O/18O labeling and the accurate mass and time tag approach. Mol Cell Proteomics 2005; 4:700-709
11. Liu T, Qian WJ, Gritsenko MA, et al: High dynamic range characterization of the trauma patient plasma proteome. Mol Cell Proteomics 2006; 5:1899-1913
12. Monroe ME, Tolić N, Jaitly N, et al: VIPER: An advanced software package to support high-throughput LC-MS peptide identifcation. Bioinformatics 2007; 23:2021-2023
13. Callister SJ, Barry RC, Adkins JN, et al: Normalization approaches for removing systematic biases associated with mass spectrometry and label-free proteomics. J Proteome Res 2006; 5:277-286
14. Nesvizhskii AI, Keller A, Kolker E, et al: A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003; 75:4646-4658
15. Kersey PJ, Duarte J, Williams A, et al: The International Protein Index: An integrated database for proteomics experiments. Proteomics 2004; 4:1985-1988
16. Hart DW, Wolf SE, Beauford RB, et al: Determinants of blood loss during primary burn excision. Surgery 2001; 130:396-402
17. Jeschke MG, Chinkes DL, Finnerty CC, et al: Pathophysiologic response to severe burn injury. Ann Surg 2008; 248:387-401
18. Sheridan RL, Schnitzer JJ: Management of the high-risk pediatric burn patient. J Pediatr Surg 2001; 36:1308-1312
19. Bernard GR, Vincent JL, Laterre P F, et al: Effcacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
20. Weintraub J, Satterwhite T, Allo M: The use of drotrecogin alfa recombinant activated protein C for severe sepsis in the critically burned patient: A new treatment approach. Burns 2006; 32:783-787
21. Price LA, Thombs B, Chen CL, et al: Liver disease in burn injury: Evidence from a national sample of 31, 338 adult patients. J Burns Wounds 2007; 7:e1
22. Jeschke MG, Klein D, Herndon DN: Insulin treatment improves the systemic infammatory reaction to severe trauma. Ann Surg 2004; 239:553-560
23. Langouche L, Van den Berghe G: Glucose metabolism and insulin therapy. Crit Care Clin 2006; 22:119-129
24. van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359-1367
25. Finnerty CC, Herndon DN, Przkora R, et al: Cytokine expression profle over time in severely burned pediatric patients. Shock 2006; 26:13-19
26. Remick DG: Cytokine therapeutics for the treatment of sepsis: Why has nothing worked? Curr Pharm Des 2003; 9:75-82
27. Chang DW, DeSanti L, Demling RH: Anticatabolic and anabolic strategies in critical illness: A review of current treatment modalities. Shock 1998; 10:155-160